TW200930385A - Composition with active ingredient combination for the treatment of constipation - Google Patents

Abstract

The invention relates to a composition comprising at least one active ingredient selected from the group of laxatives, and at least one active ingredient from the group of antifoams in combination for the therapeutic treatment of constipation. The invention further relates to the use of such a combination of active ingredients for the treatment of constipation.

Description

200930385 6 Ο 10 15 、, invention description: TECHNICAL FIELD OF THE INVENTION The present invention relates to a composition containing a combination of active ingredients for the treatment of constipation. The invention further relates to the use of active ingredients in the treatment of constipation. [Prior Art] Constipation, that is, retention of feces, occurs when the frequency of excretion is reduced; in particular, when there is less than two excretions per week. Feces are often hard and multi-blocky. Furthermore, defecation is often only possible with severe stress and pain. This may cause the patient to escape from defecation' and thus worsen the condition. There are many possible reasons for constipation. Intestinal continuation of functional disorders, which can be attributed to low fiber diets, inadequate fluid intake, and lack of exercise. Temporary constipation may be induced by interference with defecation as in an external environment (such as travel). Constipation can occur again in the symptoms of various diseases, such as diabetic constipation or associated with irritable bowel syndrome, Parkinson's disease, or multiple sclerosis. Constipation may also be a common negative effect of various pharmaceuticals, such as iron preparations, specific analgesics (especially opium), blood and heart medications, and sleeping pills and antidepressants. Various laxatives (cramps) are known for the treatment of constipation and are intended to normalize the frequency of excretion and defecation by various mechanisms of action. The goal is to soften the compressed wings and stimulate bowel movements to produce a response to bowel movements. 20 200930385 Known substances with laxative effects can be distinguished according to their mode of action as follows:

• An increased volume and swellable substance that swells through the liquid to increase the volume of the intestinal contents' such as phytoplasma, Indian plantain seed shell, linseed, wheat bran, etc.;

10 • An osmotic laxative that retains water in the intestine or removes fluid from the blood' thus increasing the water content and the volume of the intestinal contents. The stool is thus softened and the amount of feces is increased, causing swelling of the intestinal wall and stimulation of peristalsis via activation of the expansion receptor. Osmotic laxatives include salts such as Epsom (magnesium sulfate heptahydrate) and Glauber's salt (sodium sulfate decahydrate); poorly absorbable sugars and sugar alcohols such as lactose, lactulose, lactitol , sorbitol, mannitol, xylitol; and macrogol, which are combined with water and taken together with 15

Delivery to the large intestine where the feces are softened and the intestinal volume is increased to allow excretion = expansion of the flow through the intestinal wall to be mechanically induced. To avoid loss of water and electrolytes, polyethylene glycol is mixed with a physiologically concentrated electrolyte mixture (nano, potassium, magnesium, and/or touch) to produce a molar drinking solution. Affects _ sex and discharge _, which stimulates the transmission of intestinal metastasis at a rate of 20 speeds and has the effect of removing a small amount of water from the contents of the intestines. It is faster to include botanical laxatives such as aloe vera and murine. Leaves and castor oil that stimulates the intestinal wall. In addition, -w, 夂 夂 ^ 吩 系列 series of bisacodyl and sodium citrate synthetic laxatives, dragons and increased secretion of water and electrolytes, resulting in the absorption of stimulating water and stimulation of peristalsis. 4, increase volume 4 200930385 • Anti-slip agent, such as glycerin, sub-liquid paraffin and sodium dioctyl sulfosuccinate, which provide lubrication for fecal detection. • A chaotic laxative that is introduced into the intestine as a suppository, which produces a gas excretion and induces drainage through the swelling stimulus. 5 G 10 15 ❹ 20 ^ However, many of these substances (such as sugar alcohols) have been found to cause flatulence, thus damaging the well-being of affected patients. The increase in intestinal gas formation may also be caused by constipation itself, which may cause flatulence of pain. It is not possible or sufficient to reduce or eliminate the flatulence associated with flatulence or constipation caused by (4) threats. In addition, the laxatives known in the art are often associated with the disadvantages of pain and sudden defecation impulses when their action occurs. SUMMARY OF THE INVENTION The object of the present invention is based on the fact that it is provided for =' which does not produce or to a lesser extent the above disadvantages. The purpose of the = is to provide a composition of the type that is suitable for eliminating constipation and having a reduced flatulence. It is also convincing... Constipation has a (four) place. This purpose is based on the combination of the present invention =:= sexual ingredients and combinations of at least two types of agents. To. In a preferred embodiment of the invention, the combination of this group == not only makes successful treatment of constipation a cocoa but also reduces or eliminates flatulence associated with constipation. Further, there is a proposed anti-foaming agent which can positively suppress the flatulence which may be present due to the combination of the laxative component and the active ingredient in the active ingredient combination. 5_ Ο 10 15 ❹ It has been surprisingly discovered that it is possible to prevent or at least alleviate sudden and painful defecation impulses by additionally presenting an anti-foaming agent in a combination of active ingredients. In the advantageous properties described above, the compositions of the present invention differ in their overall improved tolerance. The composition of the present invention is obtained in a specific embodiment of the present invention by simultaneously taking at least one active ingredient selected from the group of laxatives and at least one active ingredient selected from the group consisting of anti-foaming agents. Preferred compositions of the present invention comprise, in a fixed combination, a combination of active ingredients in the form; this combination means that all of the ingredients forming the combination of the individual active ingredients are present together in a single dosage form and administered together. Suitable active ingredients selected from the group of anti-foaming agents are, in principle, all (four) or formulations which have significant surface activity and which are suitable for suppressing the formation or destruction of the formed foam and which are acceptable for the shot. The anti-foaming agent preferably used is a mixture of dimethyl polyoxyalkylene (di-e), hydrocutin dimethyl-polymethicone (simethic〇ne) and hydrated shisha dimethylpolyoxane. preparation. The dimethyl poly--words have different degrees of polymerization (preferably the number of dimethyl-wet). The η represents a liquid of odor. 4 filaments of the material, colorless and anhydrous garnet dimethyl polyfluorene gas and Shixi gel (dioxotomy, special about diterpene-based poly-dicarboxylic dimethyl sulphate and hydrated stone eve A mixture of stone dioxide. A T-based polyoxyalkylene acts as a physical agent in many of the repellents / 20 200930385 anti-flatulent agents and is generally physiologically acceptable as a foaming agent. Anti-foaming agent substance: c' in vivo is considered to be: methyl polydecane can be added to the known shape; and hydrated in stone. Incorporate the proportion of liquid or solid dosage form anti-bubble ball remaining, especially the second F-based polyglycolic oxygen appearance, in the native, Shi Xi domain or hydrated stone Xi Shi Ke, especially good for J0 to 25 〇 古 古之, ' And it is better to become a good (U to say a single dose of a specific composition in each case = (four) house grams, in the key, mouth: it: agent, solution, drops, foaming agent, ===: live = Divided into salt or infiltration (4) Puffing and swelling substances and moisturizing, y fΛ, 'd promotes intestinal peristalsis laxatives and = substance mixture' and natural substance quality = sex. Can be used in the present invention In particular, the plant is known to be familiar with the genus of the genus or the therapeutic use of the animal. Similarly, the appropriate dosage for the treatment is known to those skilled in the art. "The salt, or infiltration (4) agent is selected from the group consisting of: aCr〇g〇S (polyethylene glycol), especially Macrogol 4_ and no electrolyte; lactulose, lactose, sugar

Wr, s salt), bis, alcohol and xylitol; sodium decoxide sulfate h-based _ '(tetra) 1 nano, dihydro Weiner and sodium sulphate. Specially selected from the group that has anti-absorption and secretion-promoting effects and/or produces intestinal fissure 200930385 5 Ο 10 15 〇 20 The group of laxatives is the following: anthragly Cosides (such as sennoside (senn) 〇sides ) or rrangula bark slycosides ), anthrap Uinone (eg from aloe or rhubarb), em〇dins (aglyc〇nes); ramie Acid, castor oil, diphenolic laxatives, bile acids (such as deoxycholic acid) and choleretic agents (= bile motility to 'such as the constituents of Curcuma species) 〇p is particularly preferred from it. The group of laxatives are sodium bisulphate and bismuth (b1Sac〇dyl); the appropriate one is phenolphthalein. Diphenol-based laxatives have a dose-dependent effect on the secretion of electrolytes and water into the colon cavity and peristalsis of the intestines.单一 A single dose of the composition of the present invention preferably comprises from i to milligrams, particularly preferably from 5 to 1 mg of bisphenol sulphate sodium sulphate. If it is a secret, the dosage preferably contains 20 to 1 〇 〇 gram of active ingredient. The present invention in the composition of the present invention is also provided by a specific financial institution. These may in particular be Qianye, Senna, Rat Fruit, (8) Li Bark, Rhubarb Root or Celandine (Chelidcmium Caga) and extracts from these (4) or plant parts. And the phytochemicals are known to those skilled in the art, and the appropriateness of such agents = another - in the specific example of the present invention, the composition comprises ==: and T is selected from the coarse grain material having the substance 4 Uk and The following materials are: linseed cellulose, plantain-peak, wheat methyl and the composition of the invention comprises at least - 8 ^ 0385

The substance that has a sweet effect. Particularly suitable substances in this group are the following: high-viscosity paraffin. J

Ίο^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ In this aspect, it is also provided that the ingredients of the mixed ingredients, such as the anti-absorption effect, are mixed with the servant's tongue, or the vegetable filler (such as the money leaf or腐腐芽) 予 疋 疋, such as bisacodyl or sodium citrate. Composition of the Invention Further, a preferred embodiment comprises one of the following active ingredient rabbits Q, preferably a fixed combination: . Dimercapto polyoxyalkylene and/or hydrated vermiculite dimethyl polyoxyalkylene a) and bisfluent Biteable combination, or b) combined with bisacodyl and polyethylene glycol, or c) combined with sodium sulphate, or d) combined with sodium citrate and polyethylene glycol, or 15

e) in combination with senna extract or sennoside, or f) in combination with bisacodyl and lentil extract or sennoside, or g) in combination with at least one sugar alcohol, preferably selected From sugar alcohols including sorbitol, mannitol and xylitol, or h) in combination with sodium succinate or dosate sodium, or 20 i) in combination with polyethylene glycol, or j Combining with one or more salt laxatives, preferably selected from the group consisting of sodium sulfate decahydrate (Glauber's salt), sulfuric acid town (Epsom salt), barium hydroxide, sodium lauryl thioacetate, dihydrogen hydride a group of sodium dihydrogenates, or 9 200930385 k) in combination with polyethylene glycol and one or more salt laxatives, preferably selected from the group consisting of sodium sulfate decahydrate (Glauber, s salt), magnesium sulfate (Epsom) Salt), wind-oxidized town, monthly group of soil-based sodium acetate, gas scale, acid di-n-sodium and sodium dihydrogen sulfate.

10 15

The materials listed by way of example in the preceding paragraph do not represent a complete and limited list of active ingredients or active ingredient groups. It is of course also possible to use other active ingredients selected from the group of active ingredients mentioned and other active ingredient groups not mentioned herein for the purposes of the present invention. Furthermore, the active ingredients mentioned in the present invention can also be used in the form of their pharmaceutically acceptable salts. Suitable salts are: hydrochloride, hydrobromide, sodium, nitrate, sulfate, acetate, fumarate, citrate, propionate, oxalate, succinate, lactic acid Salt, butyrate, methanesulfonate, aspartate, citric acid, maleate, tartrate, tartaric acid hydrochloride. It is also understood that the composition of the present invention is a pharmaceutical composition, a pharmaceutical or a medical product and can be formulated into a solid, semi-solid or liquid dosage form, preferably a suspension (slip, syrup), an emulsion, an enema (clysma). ), gel, capsule, = terminal J, granules, lozenges, chews, sugar-coated tablets, enteric (_γ〇γ__) cereal capsules, enema ingots, suppositories or enema. A dosage form that is administered orally or rectally. The active ingredients mentioned above may be included. ^ 疋 granules, dispersion, dissolved, suspended or emulsified forms exist in the composition of the sputum, skin lL & 上 谙 于此 于此 于此 于此 于此 于此 于此 剂 剂 剂 剂 剂 剂 剂 剂 剂 且 且 且 且 且In the professional literature. 20 20093°38 Ο 1〇15 ❹ 20 Not sent m meat ~ ❶丨 观 观 篁 3 篁 篁 篁 篁 〇 〇 至 至 至 至 至 至 至 至 至 至 : : : : : : : : : : : : : : : : : : : : 〇〇 / ° Qin G 5 - weight ratio, in each case is the use of medicine to steal fii. < ίί = 已知 Γ Γ Γ : : : Γ Γ Γ Γ Γ Γ Γ 依 依 依 依 依 依 依 依 依 依 依 依 依 依 依 依 依 依 依 依 依 ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ Agent (formation of gel two! (such as Yamagata®: W glycerin, glyceryl stearate ride); antioxidants (such as anti-bad city), thickener (such as propyl propyl cellulose), pH- Correction of swords and buffer substances; adhesives (such as polyvinyl sigma ketone powder, hydroxy two methyl cellulose, polyethylene glycol), fillers (such as microcrystalline cellulose, sorbitol), Colorants, fragrances and flavorings (such as mint, vanilla, fruit), sweeteners (such as sorbitol, aspartame); solvents = water, ethanol, ethanol-water mixtures); solvents (such as glycerin) , propanediol alcohol). Wetting agents (such as sodium lauryl sulfate, polysorbate); synthetic and natural compounds such as medium chain triglycerides). The invention further relates to the use of a combination of the active ingredients comprising at least one active ingredient selected from the group of laxatives and at least one active ingredient selected from the group of anti-foaming agents for the treatment of constipation. The invention extends further to the use of the composition - as described above - comprising a combination of active ingredients for the treatment of constipation according to the invention. 11 200930385 + The combination of the active ingredients of the invention or the composition comprising the combination can be used for constipation treatment of various pathogens, duration, intensity or severity. Roots • Therapeutic uses according to the invention include the treatment of chronic and acute constipation. The present invention also extends to the treatment of constipation caused by the side effects of pharmaceuticals, in particular, during the treatment of pain with opiates; and constipation for diabetic constipation, postoperative complications, constipation in bed, constipation Treatment of constipation related to constipation, dietary changes, or knowledge-related constipation. Preferably, a preferred embodiment provides a combination of the active ingredients of the present invention or a pharmaceutical product 10 for reducing or eliminating the pain of defecation and the generation of sudden impulses. For therapeutic use, a combination of the active ingredients according to the invention is administered in a dosage form as described above, preferably by the oral or rectal route. The following dosage forms are suitable for oral administration: suspensions, lotions, gels, capsules, powders, granules, chewable tablets, foamed ingots, foaming powder ingots. 15 The following dosage forms are particularly suitable for rectal administration: suspensions, lotions, enema, enema, suppositories or infusions. The combination of the 〇/tongue component and the composition of the present invention are preferably used in human medical treatment, that is, for treating people suffering from constipation. The invention further extends to the use of a combination of the active ingredients of the present invention and a pharmaceutical product in the veterinary field, i.e., an oral treatment, which has developed a constipation treatment requirement, particularly a domestic animal or a stocked animal. The invention further comprises a method of treating a subject suffering from constipation and in need of treatment comprising at least one therapeutic step, wherein administering a hair smear (or a composition of the invention comprising a combination of active ingredients) The combination 'is preferably by the oral or rectal route. If necessary, 200930385 repeats the administration at appropriate intervals until the desired treatment result is produced. Depending on the severity of constipation, one to three single doses may be administered one or more times per day in each case. The invention extends further to preferred immobilized combinations of active ingredients, such as those described above for the manufacture of pharmaceutical or medical products for the treatment of constipation. It has been surprisingly found that the active ingredients of the combination of the invention strengthen each other in a synergistic manner. This makes it possible to reduce the dose of individual substances compared to conventional compositions for the treatment of constipation. It has also been surprisingly found that side effects (such as flatulence and sudden and painful bowel movements) are compared to the conventional pharmaceutical products mentioned. It has also been surprisingly observed that regardless of the mode of action of the laxative (i.e., all or part of it), side effects of laxative treatment are slowed, such as flatulence. EXAMPLES The present invention will be described in more detail by the formulation of the following examples: 瘆#秘的可嚼锭 Active ingredient: bisacodyl 5 mg (per tablet; total weight: 1.2 g), hydrazine hydrate Stone dimercapto polyoxyalkylene 50 mg (per tablet) Shaped agent: glyceryl monostearate, hydroxypropyl cellulose, sucrose, glucose, peppermint oil, 瘵 秘 之 之 耐 耐 Z Z Z 10 vaginosin (per ingot; total weight: 0.8 g), hydration 13 200930385 chopped dimethyl polyoxymethane 40 mg (per bond) Excipients: polyethylene σ ratio P ketone, lactose, cross-linking Carboxymethylcellulose sodium, polyethylene glycol 8000, gastric acid resistant coating (Eudragit® S100) 5 Example 3: Sterility for the treatment of constipation Active ingredient: bisacodyl 10 mg (per suppository), two Indole-based polyoxyxan 50 mg (per suppository) Excipients: medium chain glyceride, hard fat, corn starch 〇 10 Example 4 · Powder for the treatment of constipation Too active ingredient: polyethylene glycol 3350 3 Gram, hydrated vermiculite dimercapto polyoxyalkylene 0.1 g, sodium sulfate 0.3 g (anhydrous) Example 5 : For the treatment of constipation powder too active ingredients · Polyethylene glycol 3350 I3.12 gram, hydrated stone Xi Shi Diji group poly 15 Shixi oxygen burning 〇. 125 grams, 0.350 grams of sodium chloride, sodium bicarbonate 0.179 g, potassium chloride 0.046 g 赋形剂 excipient··fragrance, sweetener, glucose, sucrose, microcrystalline cellulose, hydroxyethylcellulose, etc. 20 cases 6: Same as _ Xiaojiao to Xizhixie Active ingredient of the capsule: 125 mg of hydrated vermiculite diterpene polysulfide excipient (soft capsule, gelatin, glycerol, 85%, sorbitol, and quetiapine (E104)) Dosage 200930385 / The combination of writing agent and anti-foaming agent to reduce the effect of flatulence caused by flattening agent: The market research has confirmed that patients suffering from constipation and taking laxatives complain of flatulence as well. It is strengthened by laxatives. The symptoms before defecation are: pain, cramps and swelling in the lower abdomen. It has been reported that one of the side effects of the most common laxatives (depending on the nature and dosage) is the diarrhea, which is often caused by flatulence. After that, this often leads to the loss of control of explosive defecation and defecation. In the pharmacy-based observational study (PHOBS), explore simultaneous ingestion; writing agent and hydration; 5 kiwi dimethyl polyoxyalkylene will reduce diarrhea and associated symptoms. ^ In the first phase, 20 Patients taking laxatives and flatulence were asked to report their normal treatment and constipation symptoms for 3 days. The observed parameters were: frequency of defecation and viscoelasticity of feces (hard, normal, hidden) > write), take the laxative until the time of defecation, accompanying symptoms, such as swelling and swelling of the abdomen, pain and thirst. In the second stage, the patient is required to take 125 mg of hydrazine hydrate at the same time. Polyoxane (Lefax liquid capsule, registered status: medical and its _ agent. Of the 2 people who contacted, 17 completed the first and second stages of treatment. Among these patients, 3 used bisacodyl, 4 used Peak sulfuric acid, and H) people used polyethylene glycol. Results: 15 200930385 laxatives. After three days of hospice therapy, all patients were treated as recommended by the data grass. ("The effect of sputum sulphate on sodium sulphate is faster than that of patients with polyp-fermentation 弋i (3_ after ingestion) Minutes) Two obvious:, and there is a strong urge to defecate, resulting in " Ο 10 15 : (often looking for the nearest toilet)). 3 days and hydrated Shishishi dimethyl concentrating stone The combination of sodium sulfate and the number of milk is significantly reduced - although it is lighter than the saxable and the sulphate polychlorinated diterpene glycol product and the hydrated stone Xi Shi, but the frequency of defecation is not ίί. Conclusion: The limited number of patients with pharmacy-based medicinal spleen rr hydrated Shishishi dimethyl polychlorite oxime (dimethyl and sedatives in the therapeutic dose reduced the cause of the agent The flatulence f is caused by the pain of the air force in the intestine. For example, the effect of the sputum and the defecation impulse 'LI' has nothing to do with it, but it does not damage the effect. In addition, the quality of life of the patient increases. Explanation] No [Main component symbol description] 20

Claims (1)

200930385 VII. Patent Application Range: 1. A composition comprising at least one active ingredient selected from the group of laxatives and combining at least one active ingredient selected from the group of anti-foaming agents. 2. The composition of claim 1 of the patent application, characterized in that the combination is a fixed combination. 3. The composition of claim 1 or 2, characterized in that it comprises at least one anti-foaming agent selected from the group consisting of dimercaptopolyoxyalkylene and hydrated vermiculite dimethylpolyoxane. 10 15 20. The composition of claim 1 to 3, characterized in that it comprises at least one active ingredient selected from the group consisting of salts or osmotically active laxatives, preferably selected from the group consisting of polyethylene glycol, lactulose, a group of lactose and sugar alcohol, especially sorbitol, mannitol and xylitol, and sodium sulfate decahydrate (Glauber's salt), magnesium sulfate (Epsom salt), magnesium hydroxide, sodium lauryl sulfoacetate, Disodium hydrogen phosphate, sodium dihydrogen phosphate and sodium citrate. A composition according to any one of the preceding claims, characterized in that it comprises at least one group selected from the group consisting of laxatives having anti-absorption and pro-secretory effects and laxatives for stimulating intestinal peristalsis, preferably selected from the group consisting of Including anthraglycosides, anthrapuinone, emodins, ramie 6. acid, castor oil, diphenolic laxatives, bile acids, and choleretic agents, such as the composition of claim 5, It is characterized by a package selected from the group consisting of sodium citrate, bismuth bite and ageing && at least not bismuth bite and sodium citrate. A composition according to any one of the preceding claims, which is characterized by one or more botanical laxatives, preferably selected from the group consisting of senna, for its package, for sale, and 17 200930385 Buckthorn fruit, buckthorn bark, rhubarb root and extracts of the above plant parts. 8. A composition according to any one of the preceding claims, characterized in that it comprises one or more substances selected from the group of puffed and swellable substances having a laxative effect, in particular selected from coarse grain materials. Group. A composition according to any one of the preceding claims, characterized in that it comprises one or more substances having a laxative effect selected from the group of lubricants. A composition according to any one of the preceding claims, characterized in that it comprises a dimercapto polyoxyalkylene and/or a hydrated vermiculite dimethylpolysiloxane 〇a) in combination with bisphenol. Or 10 b) in combination with bisacodyl and polyethylene glycol, or c) in combination with sodium citrate, or d) in combination with sodium citrate and polyethylene glycol, or e) with senna extract Or a combination of sennoside, or f) in combination with bisacodyl and lentil extract or sennoside, or 15 g) in combination with at least one sugar alcohol, preferably selected from the group consisting of sorbitol, mannitol and Xylitol sugar alcohol, or . ❹ h) in combination with diisooctyl succinate, or i) in combination with polyethylene glycol, or j) thirsty with one or more salts The combination of agents is preferably selected from the group consisting of sodium sulphate sulfate (Glauber's salt), sulphuric acid (Epsom salt), magnesium hydroxide, sodium lauryl sulfoacetate, disodium hydrogen phosphate, and sodium dihydrogen phosphate. Or k) in combination with polyethylene glycol and one or more salt laxatives, preferably selected from the group consisting of sodium sulfate decahydrate (Glaub) Group of er's salt), sulphuric acid town (Epsom 18 200930385. salt), magnesium hydroxide, sodium lauryl sulfoacetate, disodium hydrogen phosphate and sodium dihydrogen citrate. A composition according to any one of the preceding claims, characterized in that it is formulated as a suspension (such as drops, syrup), an emulsion, an enema (clysma), a gel, a capsule, Powders, granules, bonds, VJ granules, sugar-coated bonds, gastroresistant tablets, enteric-coated capsules, enema ingots, suppositories or enema. 12. A composition as claimed in any one of the preceding claims, characterized in that a single dose of the composition comprises from 0.1 to 500 mg, preferably from 10 to 250 mg, particularly preferably from 40 to 150 mg of diterpene. A siloxane or a hydrated vermiculite, a thiol-polyoxylate. 13. Use of a composition according to any one of claims 1 to 12 for the manufacture of a pharmaceutical composition for the treatment of constipation. 14. The use of claim 13 in the scope of patent application, characterized in that it comprises chronic, acute constipation, constipation caused by side effects of pharmaceuticals, especially during pain treatment with opiates, and diabetic constipation, constipation after surgery Constipation in bed, constipation related to intestinal dryness, dietary changes or travel-related constipation. The use of the scope of claim 13 or 14 is characterized by a combination of live points for reducing or eliminating flatulence or pain and sudden defecation. 16. A method of treating constipation, the use of which includes at least one The self-assembled active ingredient, and a combination of at least one selected from the group consisting of anti-foaming ingredients. The life of 20 200930385 Fourth, the designated representative map: (a) The representative representative of the case is: the (none) map. (2) A brief description of the component symbols of this representative figure: None 5. If there is a chemical formula in this case, please disclose the chemical formula that best shows the characteristics of the invention: